Latest Intellectual Property News

Aristocrat Leisure Limited reported a robust HY25 with revenue rising 9% to AUD 3 billion and a 6% increase in NPATA, underpinned by strategic acquisitions and operational resilience. The company signals confidence in sustained growth through innovation and market expansion.

Wellnex Life Limited reports a robust 46% revenue increase and successful AIM listing, setting the stage for UK and European expansion.

Impact Minerals has raised an additional $881,000 through a rights issue shortfall offer and completed the sale of its Blackridge project, positioning itself for upcoming drilling at Arkun and development of a high purity alumina pilot plant.

ClearVue Technologies has inked a five-year exclusive manufacturing and distribution agreement with New Zealand’s Viridian Glass, marking its strategic entry into the New Zealand market with solar-integrated glazing solutions.

Zeotech Limited has successfully completed a two-year methane control program, developing a zeolite-based biofilter that reduces landfill methane emissions by more than 90%. The company is now preparing for on-site trials and commercial deployment.

FBR Limited has completed the final tranche of its $6.3 million placement, enabling significant cost reductions and operational consolidation that position the company for a more sustainable future.

Yowie Group has announced an all-scrip off-market takeover bid for Keybridge Capital, offering one Yowie share per Keybridge share. The bid is subject to key regulatory and shareholder approvals, setting the stage for a significant consolidation in the ASX-listed consumer goods and investment sectors.

MedAdvisor Limited has entered a non-binding agreement to sell its ANZ business division for a headline price of $35 million plus a potential earn-out, marking a significant strategic shift.

Nanoveu Limited has launched a $2.7 million capital raising via a share placement and a substantial options offer, pending shareholder approval for securities issued to its Executive Chairman. The prospectus outlines key risks and the impact on the company’s capital structure.

Light & Wonder, Inc. reported steady Q1 2025 results with modest revenue growth, margin expansion, and a strategic acquisition poised to reshape its land-based gaming footprint.

Nyrada’s experimental drug NYR-BI03 shows promising cardioprotective and anti-arrhythmic effects in animal models, reinforcing its potential as a treatment for acute myocardial infarction.

Aurora Labs has reached a critical design freeze milestone under its Australian Defence Force contract, advancing its novel 3D-printed propulsion system towards testing and validation phases.